Siltartoxatug Biosimilar – Anti-Tetanus toxin mAb – Research Grade from ProteoGenix; catalogue PX-TA2214; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Siltartoxatug Biosimilar is a novel therapeutic antibody that has been developed as a biosimilar to the existing anti-tetanus toxin monoclonal antibody (mAb). This biosimilar has been designed to specifically target and neutralize the tetanus toxin, a potent neurotoxin produced by the bacteria Clostridium tetani. Siltartoxatug Biosimilar has shown promising results in pre-clinical studies and is currently being evaluated for its potential in treating tetanus infection and related diseases.
Siltartoxatug Biosimilar is a recombinant humanized IgG1 monoclonal antibody, which means that it is produced using genetic engineering techniques to create a human-like antibody that can bind to the tetanus toxin with high specificity and affinity. The antibody has a similar structure to the natural human antibody, with two heavy chains and two light chains joined by disulfide bonds. The variable regions of the antibody, responsible for binding to the tetanus toxin, have been modified to improve their binding affinity and specificity.
Additionally, Siltartoxatug Biosimilar has been engineered to have a longer half-life in the body, allowing it to remain active for a longer period of time and provide sustained protection against the tetanus toxin. This has been achieved by introducing specific amino acid substitutions in the Fc region of the antibody, which interacts with the neonatal Fc receptor to extend its half-life.
The main function of Siltartoxatug Biosimilar is to bind to the tetanus toxin and neutralize its activity. The antibody recognizes a specific epitope on the toxin and prevents it from binding to its target receptors on nerve cells, thereby blocking its neurotoxic effects. This mechanism of action is similar to that of the natural anti-tetanus toxin antibody produced by the body in response to tetanus infection.
Moreover, Siltartoxatug Biosimilar has been shown to have a high binding affinity for the tetanus toxin, which allows it to effectively neutralize even low concentrations of the toxin. This makes it a potent therapeutic agent for treating tetanus infection and related diseases.
Siltartoxatug Biosimilar has potential applications in both the prevention and treatment of tetanus infection. As a prophylactic agent, it can be used to provide passive immunity against tetanus in individuals who have not been vaccinated or have low levels of natural anti-tetanus toxin antibodies. This is particularly beneficial in emergency situations where there is a risk of tetanus exposure, such as in cases of contaminated wounds.
Furthermore, Siltartoxatug Biosimilar can also be used as a therapeutic agent in individuals who have already been infected with tetanus. It can help to neutralize the toxin and prevent further damage to the nervous system, thereby improving the chances of recovery and reducing the severity of symptoms.
In addition to its use in tetanus infection, Siltartoxatug Biosimilar has potential applications in other diseases and conditions where the tetanus toxin is involved. This includes tetanus-related diseases such as tetanus neonatorum, a form of neonatal tetanus, and tetanus-associated spastic paralysis, a condition characterized by muscle stiffness and spasms.
Siltartoxatug Biosimilar is a promising therapeutic antibody that specifically targets the tetanus toxin and has the potential to revolutionize the treatment of tetanus infection and related diseases. Its unique structure, high binding affinity, and extended half-life make it a highly effective and versatile agent for both prevention and treatment. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar, but it holds great promise
ProteoGenix catalogue number PX-TA2214. For research use only.
Target: Siltartoxatug Biosimilar – Anti-Tetanus toxin mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
